Biocon Biologics Launches YESINTEK In US For Treating Autoimmune Diseases

Biocon Biologics on Monday said it has launched a biosimilar product to treat certain autoimmune diseases, in the US market. YESINTEK (ustekinumab-kfce), which is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, is now available to patients in the US, the company said in a statement.

The company's product is biosimilar to Stelara.

"The launch of YESINTEK marks a significant step in our commitment to improving the lives of patients with inflammatory conditions and expanding access to high-quality biosimilars," Biocon Biologics chief executive officer and managing director Shreehas Tambe said.

Biocon Biologics Inc Head of North America Josh Salsi said, "For healthcare providers, switching to YESINTEK offers a seamless treatment experience covering the same indications and dosing options."